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Background: Sarcolipin is a regulator of SERCA in skeletal and atrialmusclewith inhibitory properties thought to be similar
to phospholamban.
Results: Residues critical for SERCA inhibition reside in the luminal extension of sarcolipin.
Conclusion: The luminal extension of sarcolipin is a distinct and transferrable domain that encodes most of its inhibitory
properties.
Significance: Sarcolipin and phospholamban use different inhibitory mechanisms to regulate SERCA.
The sarco(endo)plasmic reticulum calcium ATPase (SERCA)
is regulated in a tissue-dependent manner via interaction with
the short integral membrane proteins phospholamban (PLN)
and sarcolipin (SLN). Although defects in SERCA activity are
known to cause heart failure, the regulatory mechanisms
imposed by PLN and SLN could have clinical implications for
both heart and skeletal muscle diseases. PLN and SLN have sig-
nificant sequence homology in their transmembrane regions,
suggesting a similar mode of binding to SERCA. However,
unlike PLN, SLN has a conserved C-terminal luminal tail com-
posed of five amino acids (27RSYQY), whichmay contribute to a
distinct SERCA regulatory mechanism. We have functionally
characterized alanine mutants of the C-terminal tail of SLN
using co-reconstitutedproteoliposomes of SERCAandSLN.We
found that Arg27 and Tyr31 are essential for SLN function. We
also tested the effect of a truncated variant of SLN (Arg27stop)
and extended chimeras of PLN with the five luminal residues of
SLN added to its C terminus. The Arg27stop form of SLN
resulted in loss of function, whereas the PLN chimeras resulted
in superinhibition with characteristics of both PLN and SLN.
Based on our results, we propose that the C-terminal tail of SLN
is a distinct, essential domain in the regulation of SERCA and
that the functional properties of the SLN tail can be transferred
to PLN.
Sarcolipin (SLN)3 was first described as a low molecular
weight protein that co-purified with preparations of SERCA,
and it was later named to reflect its origin as a proteolipid of the
sarcoplasmic reticulum (SR) (1). SLN is the predominant regu-
lator of SERCA and calcium homeostasis in fast twitch skeletal
muscle where it may play an additional role in thermogenesis
(2). However, SLN is also expressed with phospholamban
(PLN) in the atria of the heart (3–6), which raises the possibility
of an atrium-specific ternary complex that could lead to super-
inhibition of SERCA (7). SLN is a 31-residue type I integral
membrane protein with a transmembrane domain and short
cytoplasmic and luminal domains (1). PLN is a 52-residue type
I integral membrane protein with a transmembrane domain
and a longer cytoplasmic domain but no luminal domain (8).
Given the homology between the transmembrane domains of
these proteins, it was hypothesized that SLN binds to SERCA
and alters the apparent calcium affinity of the enzyme in aman-
ner similar to PLN (9). Inhibitionwould result fromSLNand/or
PLN binding to SERCA and stabilizing an E2 calcium-free state
(10). Mixed evidence exists on whether these regulatory sub-
units dissociate (11) or remain bound to SERCA (12–14) during
calcium transport.
Historically, SLN inhibition of SERCA has been less well
characterized than PLN in part because of the assumption that
SLN uses the same mechanism as PLN to inhibit SERCA. For
PLN, SERCA inhibition is encoded by the transmembrane
domain (15, 16), whereas reversal of inhibition via phosphoryl-
ation is enabled by the cytoplasmic domain (8). For SLN, the
transmembrane domain contains residues involved in inhibi-
tory function (9), the cytoplasmic domain contains a phospho-
rylation site (17), and the luminal domain is important for SR
retention (18) and SERCA inhibition (19). However, there are
important differences in the way that SLN inhibits SERCA. For
example, some studies have found that SLN decreases themax-
imal activity (Vmax) of SERCA at saturating calcium concentra-
tions, indicating that SLN inhibition is not reversed by calcium
(19–21). In addition, two kinases have been reported to target
SLN (17, 22), although it is not firmly establishedwhether phos-
phorylation of SLN is an important physiological mechanism.
Finally, it is well documented that the inhibitory PLNmonomer
can self-associate to form pentamers. In contrast, SLN is
thought to exist primarily as a monomer, although evidence
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suggests that SLN can also oligomerize in detergent and mem-
brane environments (23, 24).
The modeled site of interaction between SLN and the calci-
um-free state of SERCAwas the same binding groove identified
for PLN (M2,M4,M6, andM9). This was based onmutagenesis
of both SERCA and SLN combined with functional measure-
ments (9) and co-immunoprecipitation studies (7). Alanine-
scanning mutagenesis of SLN revealed similarities and differ-
ences when compared with PLN. In general, mutagenesis of
SLN had lesser effects on function and did not recapitulate the
gain of function behavior associated with residues that destabi-
lize the PLN pentamer. Nonetheless, key residues in both pro-
teins were found to be important for physical association and
function. Notably, mutation of Leu8 and Asn11 in SLN resulted
in the expected loss of function seen for the comparable Leu31
and Asn34 of PLN, and mutation of the predicted phosphoryl-
ation site to glutamate (Thr5 to Glu) appeared to mimic phos-
phorylation and result in loss of function (17). Although the
remaining sampled residues were neutral or loss of function,
there are mixed observations on the functional importance of
the unique luminal tail of SLN (Fig. 1) (9, 18, 19). The C-termi-
nal sequences of PLN and SLN represent a marked difference
between these two proteins where the hydrophobicMet50-Leu-
Leu52 in PLN is replaced by themore polar Arg27-Ser-Tyr-Gln-
Tyr31 in SLN. Importantly, this latter sequence is perfectly con-
served among mammals (18).
Given the highly conserved nature of the SLN luminal tail
and our incomplete understanding of its role in SERCA inhibi-
tion, we chose to investigate this domain by the co-reconstitu-
tion of SLN mutants with SERCA into proteoliposomes.
Another motivating factor for this study was the observation
that PLN and SLN can simultaneously bind to and regulate
SERCA (7). Although superinhibition is thought to result from
the tight fit of both PLN and SLN in the SERCA binding groove
(M2, M4, M6, and M9), we hypothesized that the luminal
domain of SLN may contribute to the strong inhibitory prop-
erties of the ternary complex. This prompted us to investigate
chimeric PLN-SLNconstructs.Herein,we provide new insights
into the regulation of SERCAby theC-terminal domain of SLN.
Alanine-scanning mutagenesis of this domain revealed at least
partial loss of function associated with all residues (Arg27-Ser-
Tyr-Gln-Tyr31), and the removal of the luminal tail in an
Arg27stop construct also resulted in loss of function. Chimeric
PLN variants possessing the luminal tail of SLN caused super-
inhibition of SERCA reminiscent of studies of the PLN-SLN-
SERCA ternary complex (7). Finally, transferring the SLN lumi-
nal tail onto a generic transmembrane helix resulted in a
chimera that completely mimicked SERCA inhibition by wild-
type SLN. We conclude that the highly conserved C-terminal
tail of SLN is a primary determinant for SERCA inhibition and
that it is a distinct and transferrable functional domain.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant SLN—Recombi-
nant SLN and PLN chimeras were expressed and purified as
described previously (25) with the exception of an additional
organic extraction step for SLN purification. Briefly, following
protease digestion of the maltose-binding protein and SLN
fusion protein, trichloroacetic acid was added to a final concen-
tration of 6%. This mixture was incubated on ice for 20 min.
The precipitate was collected by centrifugation at 4 °C and sub-
sequently homogenized in a mixture of chloroform:isopropa-
nol:water (4:4:1) and incubated at room temperature for 3 h.
The organic phase, which was highly enriched in recombinant
SLN, was removed, dried to a thin film under nitrogen gas, and
resuspended in 7 M guanidine hydrochloride. Reverse-phase
HPLCwas performed as described (25), and themolecularmass
was verified by MALDI-TOF mass spectrometry (Institute for
Biomolecular Design, University of Alberta).
FIGURE 1. Sequence alignments for primary structures of SLN and PLN from representative species. The cytoplasmic, transmembrane, and luminal
domains are indicated. Sequence variations in the luminal domains, as compared tohuman sequences, are indicated inbold.Consensus sequences for SLNand
PLN were generated based on all known sequences (ClustalW).
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Synthetic Peptide Handling—Synthetic peptides (Arg27stop,
Leu9, Leu9tail, and 27RSYQY) were purchased from Biomatik
(Wilmington, DE; 95% purity grade, HPLC- and MS-verified).
Unless otherwise specified, all synthetic peptides were acety-
lated at the N terminus and amidated at the C terminus. Except
for 27RSYQY, which was solubilized in distilled H2O, all pep-
tides were solubilized in 3:1 chloroform:trifluoroethanol at a
concentration of 1 mg/ml. The peptide concentrations were
verified by quantitative amino acid analysis.
Co-reconstitution of SERCAandRecombinant SLN—Routine
procedures were used to purify SERCA1a from rabbit skeletal
muscle SR vesicles and functionally reconstitute it into proteo-
liposomes with SLN. SERCA, SLN, egg yolk phosphatidylcho-
line, and egg yolk phosphatidic acid were solubilized with octa-
ethylene glycol monododecyl ether (C12E8) to achieve final
molar stoichiometries of 1 SERCA, 6 SLN, and 195 lipids. The
co-reconstituted proteoliposomes containing SERCA and SLN
were formed by the slow removal of detergent (with SM-2
Biobeads, Bio-Rad) followed by purification on a sucrose step
gradient. The purified co-reconstituted proteoliposomes typi-
cally yield finalmolar stoichiometries of 1 SERCA, 4.5 SLN, and
120 lipids. This same procedure was used for the co-reconsti-
tution of SERCA with PLN chimeras and synthetic transmem-
brane peptides. For the co-reconstitution of SERCA in the pres-
ence of 27RSYQY peptide, the peptide in aqueous solution was
added to the reconstitutionmixture at amolar ratio of 1 SERCA
to 100 27RSYQY followed by detergent removal with SM-2
Biobeads to ensure incorporation of 27RSYQY inside the
proteoliposomes.
Activity Assays—Calcium-dependent ATPase activities of
the co-reconstituted proteoliposomes weremeasured by a cou-
pled enzyme assay (26). The coupled enzyme assay reagents
were of the highest purity available (Sigma-Aldrich). All co-re-
constituted peptide constructs were compared with a negative
control (SERCA reconstituted in the absence of SLN) and a
matched positive control (SERCA co-reconstituted in the pres-
ence of either wild-type SLN, wild-type PLN, or Leu9 peptide).
A minimum of three independent reconstitutions and activity
assays were performed for each peptide, and the calcium-de-
pendent ATPase activity was measured over a range of calcium
concentrations (0.1–10 M) for each assay. This method has
been described in detail (27). The calcium concentration at
half-maximal activity (KCa),Vmax, andHill coefficient (nH)were
calculated based on nonlinear least square fitting of the activity
data to the Hill equation using Sigma Plot software (SPSS Inc.,
Chicago, IL). Errors were calculated as the S.E. for a minimum
of three independentmeasurements. Comparison ofKCa,Vmax,
andnHparameterswas carried out using between-subjects one-
way analysis of variance followed by the Holm-Sidak test for
pairwise comparisons (Sigma Plot).
Throughout “Results” and “Discussion,” we refer to SLN and
PLN inhibition of SERCA. Inhibition is intended to reflect the
effects that SLN and PLN have on the apparent calcium affinity
of SERCA. The effects that SLN and PLN have on the maximal
activity of SERCA are considered separately.
Kinetic Simulations—Reaction rate simulations have been
described (28, 29) for the transport cycle of SERCA in the
absence and presence of PLN inhibition, and we have adopted
this approach to understand SERCA inhibition by wild-type
SLN. As before, we performed a global nonlinear regression fit
of the model of Cantilina et al. (28) to each plot of SERCA
ATPase activity versus calcium concentration using Dynafit
(Biokin Inc., Pullman, WA). Such fits were performed for co-
reconstituted wild-type SLN, which was compared with posi-
tive (SERCA co-reconstituted with wild-type PLN) and nega-
tive (SERCA alone) control samples. All reaction rate constants
were allowed to vary in the kinetic simulations, although the
SERCA activity in the presence of SLN was best fit with modi-
fications to only the three calcium binding steps in the reaction
cycle (29). Agreement between the simulated and experimental
data is indicated by the lowest residual sum of squares.
RESULTS
Wild-type PLN Versus Wild-type SLN—We first compared
the reconstitution of SERCA in the absence and presence of
recombinant human SLN (Fig. 2). The co-reconstitution
method has been used extensively to study the functional reg-
ulation of SERCA by PLN (25, 27, 29–33), and the same
approach was used herein for detailed characterization of SLN.
The reconstituted proteoliposomes contain low lipid-to-pro-
tein ratios that mimic the native SR membranes, allowing the
direct correlation of functional data (27, 29, 32, 33) with struc-
tural observations (34–36). As before, the proteoliposomes
contained a lipid-to-protein molar ratio of 120:1 and a
SERCA-to-SLNmolar ratio of4.5:1. For co-reconstitution of
PLN, this molar ratio is similar to that found in cardiac SR (33,
37, 38); however, the SLN molar ratio used is higher than that
found in skeletal SR (9). Although there is growing evidence
that SLN can form higher order oligomers (23, 24, 39), the pri-
mary reason for using a higher ratio of SLN was to facilitate
comparison with PLN variants studied previously (27, 29, 33)
and herein. We measured the calcium-dependent ATPase
activity of SERCA in the absence and presence of SLN. Proteo-
liposomes containing SERCA alone yielded a KCa of 0.46 M
and aVmax of 4.1molmg1min1. Incorporation ofwild-type
SLN into proteoliposomeswith SERCA resulted in aKCa of 0.80
M calcium and a Vmax of 2.9 mol mg1 min1 (Fig. 2 and
Table 1). Thus, in the presence of SLN, SERCA had a lower
apparent affinity for calcium (KCa of 0.34) and a lower turn-
over rate (Vmax of1.2). Comparative data for PLN indicated
that it lowers the apparent calcium affinity of SERCA to a
degree similar to that of SLN, and it has the opposite effect on
Vmax. Nonetheless, the observed inhibitory activity of wild-type
SLN in our system was consistent with previous observations
(24, 30, 40) and served as a positive control for further studies.
Kinetic Simulations—In our previous studies, we have used
kinetic reaction rate simulations to describe calcium transport
by SERCA in the absence and presence of PLN (29, 33). The
reaction scheme assumes that the binding of calcium to SERCA
occurs as two steps linked by a slow structural transition that
establishes cooperativity (E  Ca 7 ECa 7 ECa  Ca 7
E2Ca) (28, 41). The conformational change, represented by
reaction rate constants Bfor andBrev, is the primary step affected
by PLN that manifests as a decrease in the apparent calcium
affinity of SERCAand increased cooperativity for calciumbind-
ing. To provide a mechanistic framework for the function of
Luminal Domain of Sarcolipin and SERCA Regulation
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TABLE 1
Kinetic parameters for SERCA in the absence and presence of various sarcolipin mutants, chimeras, and peptides
Between-subjects one-way analysis of variance followed by the Holm-Sidak test was used for pairwise comparisons against SERCA in the absence and presence of wild-type
SLN. Note that the KCa value for SERCA in the presence of Arg27stop was not significantly different from the values determined for R27A, S28A, Y29A, Q30A, and Y31A.
Vmax KCa nH n
mol mg1 min1 M
SERCA 4.1 0.1 0.46 0.02 1.7 0.1 32
WT SLN 2.9 0.1a 0.80 0.02a 1.4 0.1 10
V26A 2.9 0.1a 0.69 0.03a 1.4 0.1 7
R27A 3.4 0.1a,b 0.51 0.01b 1.4 0.1 6
S28A 3.5 0.1a,b 0.59 0.03a,b 1.5 0.1 6
Y29A 3.2 0.1a 0.63 0.03a,b 1.3 0.1 13
Q30A 2.6 0.1a 0.60 0.04a,b 1.4 0.1 4
Y31A 4.6 0.1a,b 0.52 0.02b 1.3 0.1 5
Arg27stop 3.4 0.1a,b 0.55 0.02a,b 1.6 0.1 9
WT PLN 6.1 0.1a,b 0.88 0.03a 2.0 0.1 9
WT PLNWT SLN 3.4 0.1a,b 1.36 0.07a,b 1.7 0.1 3
cPLNlong 2.9 0.1a 2.3 0.09a,b 1.6 0.1 6
cPLNshort 2.2 0.1a,b 3.4 0.20a,b 1.9 0.1 427RSYQY 4.2 0.1b 0.41 0.02b 1.5 0.1 5
Leu9 4.4 0.1b 0.61 0.05a,b 1.6 0.1 5
Leu9tail 3.0 0.1a 0.81 0.05a 1.5 0.1 6
a p 0.05 in the absence of wild-type SLN.
b p 0.05 in the presence of wild-type SLN.
FIGURE 2. Functional data for wild-type SLN. A, topology models for wild-type SLN and wild-type PLN (white, cytosolic residues; gray, transmembrane
residues;black, luminal residues). ShownareATPase activity (B) andnormalizedATPase activity (C) as a functionof calciumconcentration for SERCAalone (solid
black line), SERCA in the presence of wild-type SLN (solid gray line), and SERCA in the presence of wild-type PLN (dashed line). The curves fitted to the
experimental data are from a global nonlinear regression fit of SERCA reaction rate constants (28) to each plot of ATPase activity versus calcium concentration.
TheVmax, KCa, and nH are given in Table 1. Each data point is themean S.E. (error bars) (n 4).D, kinetic simulations highlighting the differences between PLN
and SLN. Starting from values determined for wild-type PLN (Table 2 and Ref. 29), simulations were performed allowing all reaction rate constants to vary
(solid black line), allowing only Brev to vary (Fit 1; solid gray line), or allowing only Bfor and Brev to vary (Fit 2; dashed line). The reaction rate constants are
given in Table 2.
Luminal Domain of Sarcolipin and SERCA Regulation
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SLN, we used the same approach to gain further insight into the
subtle differences between SLN and PLN regulation of SERCA
(Fig. 2 and Table 2). Our kinetic analyses revealed that wild-
type SLN targets the first two reaction steps, binding of the first
calcium ion (Afor and Arev) and the subsequent conformational
transition (Bfor and Brev).
E  Ca -|0
Afor
Arev
ECa -|0
Bfor
Brev
ECa Ca -|0
Cfor
Crev
ECaCa
REACTION 1
A dramatic increase in Arev was observed, indicating that SLN
decreases the apparent calciumaffinity of SERCAbydriving the
enzyme toward a calcium-free conformation. SLN also
decreased the forward rate constant for the SERCA conforma-
tional change (Bfor), indicating that SLN lowers the maximal
activity of SERCA by making this reaction step less favorable.
To test whether our kinetic simulations for wild-type SLNwere
reliable, we ran additional simulations starting from the reac-
tion rate constants determined for SERCA in the presence of
wild-type PLN (28, 29). Holding all reaction rates constant and
allowing only Bfor and Brev to vary, we attempted to force the
simulation to fit the wild-type SLN experimental data with
reaction rate constants that were similar to those found for
wild-type PLN. These simulations resulted in poor fits to the
experimental data (Fig. 2D).
It is interesting to compare the kinetic simulations for SLN
and PLN. The primary effect of SLN is to make binding of the
first calcium ion less favorable, thereby stabilizing a calcium-
free conformation of SERCA. In contrast, the primary effect of
PLN is to displace the SERCA ECa-ECa conformational equi-
librium toward ECa, which has the additional consequence of
enhancing cooperativity. In addition, our simulations indicate
that the opposite effects that SLN and PLN have on the maxi-
mal activity of SERCA can be explained by an opposite effect on
Bfor (SLN decreased Bfor and PLN increased Bfor). This latter
observation is consistent with the notion that PLN (12, 14, 42,
43) and SLN (2) remain associated with SERCA at saturating
calcium concentrations.
Alanine Substitutions in the Luminal Domain of SLN—The
presence of the unique luminal domain in SLN as well as the
high degree of conservation of its sequence could suggest that
all of these amino acids might be required for regulation of
SERCA. As a first step in examining the role of the luminal tail
of SLN, we systematically mutated residues 26–31 of SLN to
alanine, co-reconstituted each mutant with SERCA, and meas-
ured the calcium-dependent ATPase activity of the proteolipo-
somes (Fig. 3 and Table 1). For effective comparison of the
calcium-dependent ATPase activity of SERCA in the presence
of SLNmutants, we wished to confirm that each of themutants
was reconstituted into proteoliposomes with the same effi-
ciency as wild-type SLN. To that end, we used quantitative gel
electrophoresis to monitor the levels of SERCA and SLN in the
proteoliposomes (27, 29). Incorporation of each of the SLN
mutants did not significantly differ from wild type (Fig. 3A),
indicating that any observed differences in SERCA function
could be attributed to the SLN mutation.
Alanine substitution of any residue within the 27RSYQY
motif had a negative impact on the ability of SLN to alter the
apparent calcium affinity of SERCA, whereas substitution of
the preceding residue, Val26, had a lesser effect. Although
valine-to-alanine mutation is a conservative substitution, we
could compare our results with mutation of the homologous
residue in PLN (Val49; Fig. 1). The Val26-to-Ala mutant also
served as an internal comparison for the luminal tail mutants
described below. As expected, alanine substitution of Val26 had
only a minor effect on the inhibitory properties of SLN, result-
ing in mild loss of function (KCa of 0.69M compared with 0.80
M calcium for wild type; KCa of 0.11). This compared well
with findings for PLNwhere alanine substitution of the homol-
ogous position, Val49, has also been shown to have a mild effect
on PLN function (29, 44). Thus, we concluded that Val26 is part
of the transmembrane domain and not the tail region of SLN.
For mutations within the luminal tail domain, the two most
severe alanine substitutions were Arg27 to Ala and Tyr31 to Ala,
which resulted in nearly complete loss of SERCA inhibition
(KCa of 0.51 and 0.52Mcalcium;KCa of 0.05 and 0.06, respec-
tively). Thesemutants were determined to be the strongest loss
of functionmutations in the luminal domain of SLN, indicating
the importance of a positively charged residue at themembrane
surface and a more distal aromatic residue. Interestingly, these
mutants had distinct effects on the maximal activity of SERCA.
Given the ability of wild-type SLN to reduce themaximal activ-
ity of SERCA (Fig. 3 and Table 1), the Arg27-to-Ala mutant
resulted in a slight loss of this behavior, and the Tyr31-to-Ala
mutant resulted in a complete loss of this behavior. In fact, the
Tyr31-to-Ala mutant had the opposite effect in that it caused a
slight increase in the maximal activity of SERCA. Compare the
Vmax values for SERCA alone (4.1 mol mg1 min1), SERCA
in the presence of wild-type SLN (2.9 mol mg1 min1),
SERCA in the presence of Arg27-to-Ala SLN (3.4 mol mg1
TABLE 2
Rate constants from kinetic simulations (s1)
Afor Arev Bfor Brev Cfor Crev Sum of squares
SERCA 190,000 400 30 40 1,810,000 16 0.002
WT PLN 190,000 400 45 25,500 250,000 16 0.004
WT SLN 156,530 64,736 22 135,140 1,810,000 16 0.001
Alternate fits in Fig. 2Da
Fit 1 190,000 400 45 1,133,000 250,000 16 0.327
Fit 2 190,000 400 22 60,562 250,000 16 0.03
aOnly the values in bold were allowed to vary in the kinetic simulations.
Luminal Domain of Sarcolipin and SERCA Regulation
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min1), and SERCA in the presence of Tyr31 to Ala (4.6 mol
mg1 min1).
Alanine mutants of the remaining residues (Ser28, Tyr29, and
Gln30) deviated from wild-type behavior with variable effects
on the apparent calciumaffinity andmaximal activity of SERCA
(Fig. 3). In terms of their effects on the apparent calcium affinity
of SERCA, the mutants resulted in a comparable partial loss of
function. Ranking these luminal tail residues in order of impor-
tance yielded Ser28  Tyr29  Gln30. In terms of the maximal
activity of SERCA, the mutants had differential effects with the
rank order of importance being Ser28  Tyr29  Gln30. Based
on these observations, we concluded that alanine substitution
at any position in the SLN luminal tail results in loss of function,
indicating a crucial role of each of the five luminal residues in
proper regulation of SERCA. Clearly, Tyr31 was themost essen-
tial residue for altering the apparent calcium affinity and
depressing the maximal activity of SERCA. This suggests that,
in addition to contributing to SERCA inhibition, the residues
Ser28, Tyr29, and Gln30 may play a role in the proper positing of
Tyr31.
It should be noted that the SLN luminal tail was examined in
a previous study using HEK-293 cells and co-expression with
SERCA (9). Alanine substitution of the luminal tail residueswas
found to have aminimal impact on SERCA activity, which con-
trasts with our findings described above. However, it was later
shown thatmutations in the SLN tail affect the retention of SLN
in the endoplasmic reticulum of HEK-293 cells (18) such that
improper trafficking of SLN may have been an unappreciated
factor in the previous study. In addition, the previous study
measured calcium transport activity of SERCA, whereas we
have measured ATPase activity. Recent evidence suggests that
SLN may play a role in thermogenesis by uncoupling SERCA
ATPase activity from calcium transport (2).
Removal of the SLN Luminal Tail (Arg27stop)—Because all of
the alanine substitutions in the SLN luminal domain created
defects in SERCAregulation,wenext chose to remove the lumi-
nal tail and test the inhibitory capacity of the transmembrane
domain of SLN alone. For comparative purposes, recall that
80% of the inhibitory activity of PLN is encoded by its trans-
membrane domain (29). To this end, a truncated variant of
SLN, Arg27stop, missing the last five C-terminal amino acids
(27RSYQY) was generated by chemical synthesis. During syn-
thesis, the C terminus was amidated to avoid a free carboxyl at
the end of the transmembrane domain. Incorporation of
Arg27stop into proteoliposomes with SERCA proceeded nor-
mally, and the final SERCA-to-peptide ratio was comparable
with that for wild-type SLN (data not shown). The effect of this
peptide on SERCA activity wasmeasured in the same fashion as
the alanine mutants described above. As one might expect
given the results from alanine mutagenesis, the complete
removal of the luminal tail resulted in major loss of SLN func-
tion (Fig. 4 and Table 1). The KCa of SERCA was 0.55 M cal-
cium in the presence of Arg27stop compared with 0.80 M cal-
cium in the presence of wild-type SLN (26% of wild-type
inhibitory capacity). Note that the KCa value for Arg27stop is
not significantly different from the alanine substitutions dis-
cussed above. Arg27stop also resulted in a partial recovery of the
maximal activity with a Vmax value halfway between that of
SERCA alone and SERCA in the presence of wild-type SLN.
The large change in the inhibitory potency of Arg27stop agrees
with the alanine substitution data and further demonstrates the
necessity of the luminal domain of SLN in SERCA regulation.
Interestingly, the luminal tail of SLN rather than the transmem-
brane domain appeared to encode most of the inhibitory prop-
erties of SLN. This contrasts with PLN where the inhibitory
properties are encoded by the transmembrane domain. This
was a surprising finding given that SLN and PLN have homol-
ogous transmembrane domains, which are thought to interact
with the same site on SERCA and use a similar mechanism of
inhibition.
FIGURE3.Theeffectsofalaninemutation in the luminaldomainofSLNon
the KCa and Vmax of SERCA. A, SDS-PAGE of co-reconstituted proteolipo-
somes. The top gel shows the incorporation of SERCA (2 g of co-reconsti-
tuted proteoliposomes were loaded onto a 10% gel and stained with Coo-
massie). The bottom gel shows the incorporation of wild-type and mutant
SLN (2 g of co-reconstituted proteoliposomes were loaded onto a 16% gel
and stained with silver). KCa (B) and Vmax (C) values were determined from
ATPase activity measurements for SERCA in the absence and presence of
wild-type and mutant forms of SLN. Each data point is the mean S.E. (error
bars) (n  4). The Vmax, KCa, and nH are given in Table 1. Asterisks indicate
comparisons against wild-type SLN (p 0.05).
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Adding the SLN Luminal Tail to PLN—If the luminal domain
encodes the inhibitory properties of SLN, we wondered what
would happen if the luminal tail were transferred to the homol-
ogous PLN. To test this idea, two chimeric peptides were con-
structed fromwild-type PLN, onewith the five luminal residues
of SLN (27RSYQY) added to the C terminus (cPLNlong) and one
with the luminal residues added after Val49 of PLN (cPLNshort).
This latter construct placed the luminal tail of SLN at the
homologous position in PLN (Fig. 1 and Fig. 5). The calcium-
dependent ATPase activity was measured for SERCA in the
presence of the chimeras where SERCA alone served as a neg-
ative control and SERCA in the presence of wild-type PLN
served as a positive control (Fig. 5 and Table 1). Including wild-
type PLN in proteoliposomes with SERCA resulted in the
expected decrease in the apparent calcium affinity of SERCA
(KCa of 0.42 M calcium) and increase in the maximal activity
of SERCA (from 4.1 to 6.1 mol mg1 min1). Compared with
wild-type PLN, including the chimeras in proteoliposomes
resulted in superinhibition of SERCA (KCa values of 1.84 M
calcium for cPLNlong and 2.94 M calcium for cPLNshort).
Importantly, both chimeras also resulted in a decrease in the
maximal activity of SERCA that was comparable withwild-type
SLN. This was in marked contrast to the increase in SERCA
maximal activity observed with wild-type PLN in the co-recon-
stituted proteoliposomes (27, 29, 33). Thus, adding the SLN
luminal tail to PLN had a synergistic effect on the apparent
calcium affinity of SERCA and an SLN-like effect on the maxi-
mal activity of SERCA. Although both PLN chimeras were
superinhibitory, the cPLNshort construct resulted in a much
larger shift in the apparent calcium affinity of SERCA. The
potent inhibition by cPLNshort may be due to better positioning
of the SLN luminal tail and the fact that this chimera appears to
be monomeric by SDS-PAGE (Fig. 5D).
FIGURE 4. Removing the luminal tail of SLN. A, topologymodel for Arg27stop
SLN(white, cytosolic residues;gray, transmembraneresidues).KCa (B) andVmax (C)
values were determined from ATPase activity measurements for SERCA in the
absenceandpresenceofArg27stopSLN. Eachdatapoint is themeanS.E. (error
bars) (n4). TheVmax,KCa, andnH aregiven in Table 1.Asterisks indicate compar-
isons against SERCA in the absence and presence of wild-type SLN (p 0.05).
FIGURE5.Transferring the luminal tail of SLN toPLN.A, topologymodels of cPLNlong and cPLNshort chimeras (white, cytosolic residues;gray, transmembrane
residues;black, luminal residues). ShownareATPase activity (B) andnormalizedATPase activity (C) as a functionof calciumconcentration for SERCAalone (solid
black line), SERCA in the presence of wild-type PLN (solid gray line), and SERCA in the presence of cPLNlong (dashed black line) and cPLNshort (dotted black line).
Each data point is the mean S.E. (error bars) (n 4). The Vmax, KCa, and nH are given in Table 1. D, SDS-PAGE of cPLNlong (left lane) and cPLNshort (right lane)
chimeras (5 g per lane; 16% gel). Pentameric and monomeric PLN chimeras are indicated.
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The SLNLuminalTail Is aDistinct FunctionalDomain—The
experiments thus far seemed to indicate that the luminal
domain of SLN encodes most of its inhibitory activity. To test
the inhibitory properties of this domain in isolation, we synthe-
sized a peptide corresponding to 27RSYQYwith an acetylatedN
terminus. Previous work by others has demonstrated that such
a peptide can decrease the maximal activity of SERCA albeit
under excess peptide conditions (1000-fold (19)). Herein, the
soluble peptide was co-reconstitutedwith SERCA such that the
peptide was on the interior of the proteoliposomes with access
to the luminal region of SERCA, and excess peptide on the
exterior of the proteoliposomes was removed by sucrose gradi-
ent purification. Although SERCA was treated with up to a
100-fold molar excess of peptide prior to reconstitution, this
had no effect on SERCA activity (Table 1). These data indicate
that the 27RSYQY peptide by itself did not result in the robust
SERCA regulation observed for wild-type SLN or the PLN-SLN
chimeras. Similar findings have been reported for the cytoplas-
mic domain of PLN, which does not appear to regulate SERCA
as an isolated, soluble domain (16, 45).
The transmembrane helix of SLN tethers the luminal domain
to the membrane surface and provides a high local concentra-
tion relative to SERCA.As such, a soluble peptidemay be a poor
mimic of this domain. To bring the luminal domain to the
membrane surface, we tethered the 27RSYQYmotif to a model
transmembrane helix. We have previously characterized a syn-
thetic leucine-alanine peptide that contains all of the naturally
occurring leucine residues in the transmembrane domain of
PLN with all other residues substituted with alanine (desig-
nated Leu9). A variety of generic transmembrane peptides
including Leu9 have been found to beweak inhibitors of SERCA
(25, 31). To test the action of the luminal tail of SLN on SERCA
activity, we synthesized a peptide that contained the Leu9
sequencewith the five luminal residues of SLN at its C terminus
(Fig. 6; designated Leu9tail). Because the Leu9 peptide has been
characterized (31), it served as a positive control for our studies
of the Leu9tail peptide. In the co-reconstituted proteolipo-
somes, Leu9 had a slight effect on the apparent calcium affinity
of SERCA (KCa of 0.15 M calcium; 36% of wild-type PLN
inhibitory activity) and a small effect on the maximal activity of
SERCA. Inclusion of the SLN luminal tail significantly
increased the inhibitory capacity of the Leu9 peptide (KCa of
0.35 M calcium compared with KCa of 0.34 M for wild-type
SLN) and reduced the maximal activity of SERCA to the same
degree as wild-type SLN. Compare the Vmax values for SERCA
alone (4.1 mol mg1 min1), SERCA in the presence of Leu9
(4.4 mol mg1 min1), SERCA in the presence of wild-type
SLN (2.9 mol mg1 min1), and SERCA in the presence of
Leu9tail (3.0 mol mg1 min1). These observations support
the notion that the luminal tail encodes much of the inhibitory
properties of SLN and that it is a distinct and transferrable
regulatory domain.
DISCUSSION
Wild-type PLN Versus Wild-type SLN—Based on the avail-
able evidence, it was reasonable to assume that SLN and PLN
would use similar inhibitory mechanisms to regulate SERCA.
As such, SLN and PLN could represent redundant regulatory
subunits separated by distinct tissue distributionswith SLNpri-
marily in skeletal muscle and PLN in cardiac and smooth mus-
cle. As an endogenous inhibitor of SERCA, SLN plays a central
role in regulating calcium transport in skeletal muscle. How-
ever, SLN is co-expressed in atrial muscle along with PLN
(3–6), which raises questions about why redundant regulatory
mechanisms would be required in this tissue. As has been
shown for PLN, SLN alters the apparent calcium affinity of
SERCA albeit to a lesser degree (Fig. 2 and Ref. 9). PLN is highly
conserved among mammalian species with a transmembrane
domain that encodes SERCA inhibition and a cytoplasmic
FIGURE 6. Transferring the luminal tail of SLN to a generic transmem-
branehelix.A, topologymodel of Leu9 andLeu9tail (white, cytosolic residues;
gray, transmembrane residues; black, luminal residues). KCa (B) and Vmax (C)
valueswere determined fromATPase activitymeasurements for SERCA in the
absence and presence of Leu9 and Leu9tail. For comparative purposes, the
black lines indicate the values for SERCA alone, and the gray lines indicate
values for SERCA in the presence ofwild-type SLN. Notice that Leu9tail closely
recapitulates wild-type SLN. Each data point is the mean  S.E. (error bars)
(n 4). The Vmax, KCa, and nH are given in Table 1. Asterisks indicate compari-
sons against wild-type SLN (p 0.05).
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domain that is a target for regulation. SLN is also highly con-
served with a transmembrane domain analogous to that in
PLN, a short cytoplasmic domain that is a target for regulation,
and a unique, highly conserved luminal domain. Given these
similarities and differences between SLN and PLN, it is impor-
tant to understand the regulatory mechanism of SLN with
potential relevance for heart and skeletal muscle diseases.
Because this is our first detailed characterization of SLN,
it is important to consider aspects of the experimental sys-
tem, namely co-reconstituted proteoliposomes containing
SERCA1a and recombinant SLN. Such proteoliposomes have
been extensively used by us (27, 29, 32–36, 46) and others (16,
47–52) for the detailed characterization of PLN structure and
function. They contain SERCA-to-lipid molar ratios that
approximate SR membranes, and the inclusion of PLN in these
proteoliposomes has the expected effect on the apparent cal-
cium affinity of SERCA (28). At these low lipid-to-protein
ratios, PLN has an additional effect on the maximal activity of
SERCA (27, 29, 51). As shown herein, SLN is readily incorpo-
rated into the proteoliposomes, and we observed the expected
effect on the apparent calcium affinity of SERCA (Fig. 3) (9). In
contrast to PLN, SLN has an opposite effect on the maximal
activity of SERCA.
Using the proteoliposomes described above, we found that
wild-type SLN altered the apparent calcium affinity of SERCA
at a level equivalent to80% of the inhibitory capacity of wild-
type PLN. Interestingly, the SERCA inhibition by wild-type
SLN is comparable with what is observed for peptides encoding
only the transmembrane domain of PLN (31, 53, 54). Nonethe-
less, in contrast to what is observed for PLN, SLN decreased the
maximal activity of SERCA (Fig. 2 and Table 1). Given these
differential effects on SERCA activity, we used kinetic simula-
tions to identify SERCA reaction steps that may be altered by
SLN. In this regard, PLN is known to alter a SERCA conforma-
tional change that follows binding of the first calcium ion,
thereby establishing cooperativity for binding of a second cal-
cium ion (28, 29). Surprisingly, we found that SLN does not fit
this kinetic model. Instead, SLN stabilizes a calcium-free con-
formation of SERCA by altering the binding of the first calcium
ion. Combined with the observed decrease in the maximal
activity of SERCA, we concluded that SLN uses an inhibitory
mechanism that is distinct from that used by PLN.
SLN Structural Elements Involved in SERCA Inhibition—Be-
cause SLN appeared to use a unique mechanism to regulate
SERCA, it was important to identify the structural features that
encode this behavior. There are nine invariant residues in SLN
that mainly occur in the transmembrane domain (Fig. 1), and
only four of these residues are invariant in the homologue PLN.
The short cytoplasmic domain of SLN is variable across a wide
range of species, whereas the luminal domain exhibits a high
degree of conservation particularly among mammals. Alanine-
scanning mutagenesis of the luminal domain revealed that
Arg27 and Tyr31 are the two most essential residues for SERCA
regulation; both residues are required for the effect on the
apparent calcium affinity of SERCA, and Tyr31 is required for
the effect on the maximal activity of SERCA (Fig. 3). The inter-
action of Tyr31 with SERCA has been recognized (19), although
another study did not identify luminal residues as important for
SLN inhibitory function (9). Nonetheless, we found that muta-
tion of either Arg27 or Tyr31 strongly suppressed SERCA inhi-
bition by SLN. Onemight predict that Arg27 could reside at the
membrane interface and therefore aid in positioning of SLN
relative to SERCA and the lipid bilayer. Alanine substitution
would remove the positively charged side chain and extend the
hydrophobic surface of the transmembrane domain of SLN,
thereby causing misalignment of SLN within the binding
groove of SERCA (M2, M4, M6, and M9).
It is interesting to notice that the nature of the critical resi-
dues, Arg27 and Tyr31, suggest that cation- or - interac-
tionsmight be involved in the SERCA-SLN inhibitory complex.
By analogy with PLN, the C terminus of SLN is thought to
interact with the luminal end of the M2 transmembrane seg-
ment of SERCA (55). Toward the luminal end of the M1-M2
region, there are five aromatic residues, Phe73, Trp77, and Phe78
on M1 and Phe88 and Phe92 on M2. Phe88 and Phe92 on M2
flank an interaction site identified for PLN where Val89 of
SERCA was cross-linked to Val49 of PLN (55, 56). Val49 of PLN
is equivalent to Val26 of SLN; thus, Arg27, Tyr29, and Tyr31 of
SLN may be proximal to Phe88 and Phe92 of SERCA (Fig. 7).
Arg27 may form a cation- interaction with Phe92, whereas
Tyr29 and/or Tyr31 may form a cation- or -stacking interac-
tions with Phe88. Given that the M1-M2 region of SERCA
undergoes large structural rearrangements as the enzyme tran-
sitions from the calcium-free E2 state to the calcium-bound E1
state, these molecular interactions could explain the important
inhibitory role of the luminal residues of SLN.
FIGURE 7. Model showing the proximity of the luminal domain of SLN
(Arg27, Tyr29, and Tyr31 are magenta) to the luminal end of M1-M2 of
SERCA (particularly Phe88 andPhe92, which are inblue). SERCA is in the E2
conformation (60). SLN is shown as a continuous -helix, although we antic-
ipate that the luminal tail may be partially unwound in the SERCA-SLN inhib-
itory complex. Based on models for the SERCA-PLN inhibitory complex (46,
61), SLNwas aligned in theM2,M4,M6, andM9binding groove of SERCA. The
positions of Arg27, Tyr29, and Tyr31 are the approximate positions in the
molecular model constructed by Asahi et al. (7).
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The Luminal Extension of SLN Is aDistinct andTransferrable
Regulatory Domain—There are several roles that have been
suggested for the luminal domain of SLN, including SR reten-
tion and functional interaction with SERCA. For PLN, SR
retention occurs via the diarginine motif in its cytoplasmic
domain as well as through the direct interaction with SERCA
(57). The luminal 27RSYQY sequence of SLNhas been shown to
be involved in SR retention, although the interaction with
SERCA may also be a retention mechanism (18). There have
been mixed reports on the inhibitory contributions of the SLN
luminal domain (9, 19). Co-expression of SERCA and SLN
mutants in HEK-293 cells revealed minor contributions of the
C-terminal residues where loss of function occurred only when
both Tyr29 and Tyr31 weremutated (9). Endoplasmic reticulum
retention may have been affected in this study (18). Another
study highlighted the importance of the two luminal aromatic
residues in regulating SERCA. Using solid-state NMR com-
bined with functional measurements, a soluble 27RSYQY pep-
tide was shown to interact with SERCA and lower its maximal
activity (19). Therewas no effect of this peptide on the apparent
calcium affinity of SERCA. In contrast, our results indicate that
the luminal domain of SLN alters both themaximal activity and
apparent calcium affinity of SERCA. Given these disparate
observations, we sought another experimental approach to elu-
cidate the regulatory capacity of the SLN luminal domain.
To test the functional contributions of this domain, two
PLN-SLN chimeras were constructed. The first construct pos-
sessed the 27RSYQY sequence added to the C terminus of wild-
type PLN. In the context of the chimera, the full-length PLN
sequence was expected to retain wild-type functional proper-
ties, and the functional effects of the SLN luminal domain were
expected to be additive. The second construct possessed the
27RSYQY sequence added after Val49 of PLN, effectively replac-
ing the C-terminal 50MLL sequence. In the context of this chi-
mera, the shortened PLN sequence might alter its functional
properties; however, the SLN luminal domain would be opti-
mally positioned for interaction with SERCA. To our surprise,
both chimeras turned out to be potent superinhibitors of
SERCA where the luminal domain of SLN had a synergistic
effect on PLN inhibitory function. In fact, the chimeras were
reminiscent of the superinhibition observed for the ternary
SERCA-PLN-SLN complex (7) thought to exist in the atria.
These observations are consistent with the mutagenesis data
described above and support the notion that the luminal
domain of SLN possesses inhibitory activity. Although the chi-
meras were reminiscent of the ternary complex, they were
much more potent inhibitors of SERCA. Comparing the values
in Table 1, the KCa values were 0.9 M calcium for the ternary
complex, 1.84M calcium for the long chimera (cPLNlong), and
2.94 M calcium for the short chimera (cPLNshort). In the ter-
nary complex, PLN and SLN are thought to interact with
SERCA as well as each other (7), and this may create steric
restrictions that impact the proper positioning of critical regu-
latory domains, the transmembrane domain of PLN and the
luminal domain of SLN. However, in the context of the chime-
ras, both the transmembrane domain of PLN and the luminal
domain of SLNmay be properly positioned in the SERCA bind-
ing groove (M2, M4 M6, and M9 (7)). Because these two
domains use distinct mechanisms to regulate SERCA, the com-
bined effect could result in the observed superinhibition. It is
also noteworthy that by SDS-PAGE the short chimera is largely
monomeric, which could contribute to the superinhibition
seen for this construct.
Although the PLN-SLN chimeras were consistent with a
functional role for the luminal domain of SLN, this was one of
several potential explanations for the observed superinhibition.
There are a variety of ways to convert PLN into a superinhibitor
of SERCA that might not reflect a functional contribution from
the luminal 27RSYQY sequence. PLN superinhibition can result
frommutation (27, 58), depolymerization of the PLN pentamer
(44, 59), and reverse engineering of PLN peptides (25, 31). If the
luminal region of SLN is an independent functional and struc-
tural domain, it should be able to regulate SERCA in the
absence of either the SLN or PLN transmembrane domain.
However, a soluble 27RSYQY peptide by itself did not alter
SERCA activity over a range of excess concentrations. Thismay
not be surprising because the luminal 27RSYQY sequence is
normally tethered to the SR membrane. To further test the
luminal domain as an independent functional entity, we teth-
ered the 27RSYQY sequence to a model transmembrane pep-
tide designated Leu9 (31). Using a reverse engineering
approach, Leu9 was derived from the PLN transmembrane
sequence where the nine leucine residues were retained and all
other residues were mutated to alanine. This peptide is a weak
inhibitor of SERCA with 36% of wild-type PLN inhibitory
activity. Adding the luminal tail of SLN to Leu9 generated a
construct that was indistinguishable from wild-type SLN
(Table 1 and Fig. 6). Compare the KCa and Vmax values for
SERCA in the presence of Leu9tail (0.81 M calcium and 3.0
mol mg1 min1) and SERCA in the presence of wild-type
SLN (0.80 M calcium and 2.9 mol mg1 min1). These data
clearly demonstrate that the luminal region of SLN is a distinct
structural and functional domain.
In summary, critical determinants for SLN inhibitory func-
tion are found in its unique and conserved luminal tail. The
structural elements that may contribute to the formation of a
SERCA-SLN inhibitory complex include Arg27, Tyr29, and
Tyr31 of SLN and a series of aromatic residues at the base of
M1-M2 of SERCA (particularly Phe88 and Phe92). Thesemolec-
ular interactions account formuch of the inhibitory function of
SLN, and this contrasts sharply with what is known for PLN.
The transmembrane domain of PLN encodes 80% of its
inhibitory activity, whereas 75% of the inhibitory activity of
SLN is encoded by the luminal tail. These distinct structural
elements that are used by PLN and SLN to regulate SERCA
translate into different inhibitory mechanisms (28, 29). PLN
slows a SERCA conformational transition that follows binding
of the first calcium ion and establishes cooperativity for binding
of a second calcium ion. SLN alters binding of the first calcium
ion, thereby stabilizing a calcium-free conformation of SERCA.
Given that these functional properties can be transferred to
PLN or a generic transmembrane helix, we conclude that the
luminal tail of SLN is a distinct, essential, and transferrable
regulatory domain.
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